Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
SHC adaptor protein 4 (SHC4) is a member of the Shc family of adaptor proteins, which are intracellular molecules lacking intrinsic enzymatic activity and containing phosphotyrosine-binding (PTB) and Src homology 2 (SH2) domains[1][2]. SHC4 functions by mediating protein-protein interactions, transmitting signals from activated cell surface receptors (such as receptor tyrosine kinases) to intracellular signaling cascades, including the Ras/MAPK pathway. It has roles in promoting cell proliferation, differentiation, migration, apoptosis, and oxidative stress responses, and is implicated in tumor development and neurological function[1][2]. SHC4 is considered a potential therapeutic target, but currently there are no known drugs that target it directly or established biomarkers tied to its activity[2]. Dysfunction or deregulation of SHC4 and related proteins has been implicated in cancer, neurodegenerative diseases, and behavioral disorders[1][2].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on SHC adaptor protein 4 (SHC4).